Hatswell AJ, Baio G, Berlin JA, et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ open 2016;6:e011666 10.1136/bmjopen-2016-011666 
 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10.
 INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE. ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSIS IN CLINICAL TRIALS TO THE GUIDELINE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9(R1).
 Rittberg R, Czaykowski P, Niraula S. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies. JNCI Cancer Spectrum 2021;5:pkab061 10.1093/jncics/pkab061 
 FDA/CDER/mccrayk. Rare Diseases: Common Issues in Drug Development: Guidance for Industry ;
 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Choice of control group and related issues in clinical trials E10 2000.
 Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet 2016;387:1909–20 10.1016/S0140-6736(16)00561-4
 Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet 2018;391:748–57 10.1016/S0140-6736(17)33297-X 
 Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 2012;15:940–47 10.1016/j.jval.2012.05.004 
 Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics 2010;28:935–45 10.2165/11538370-000000000-00000 
 David M. Phillippo, A. E. Ades, Sofia Dias, Stephen Palmer, Keith R. Abrams, Nicky J. Welton. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE 2016.
 Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clin Cancer Res 2013;19:2613–20 10.1158/1078-0432.CCR-12-2938 
 Denne JS, Stone AM, Bailey-Iacona R, et al. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials. Journal of biopharmaceutical statistics 2013;23:951–70 10.1080/10543406.2013.813515 
 Marks HM. A rational therapeutics: Science and the reform of therapeutics in the United States, 1900-1990. Cambridge England, New York: Cambridge University Press 1997 ISBN:0521581427;
 Carrigan G, Whipple S, Capra WB, et al. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. Clin Pharmacol Ther 2020;107:369–77 10.1002/cpt.1586 
 Ribeiro TB, Colunga-Lozano LE, Araujo APV, et al. Single-arm clinical trials that supported FDA Accelerated Approvals have modest effect sizes and at high risk of bias. Journal of Clinical Epidemiology 2022 10.1016/j.jclinepi.2022.01.018